Robbins K T, Vu T P, Diaz A, Varki N M
Department of Otolaryngology-Head and Neck Surgery, University of Tennessee, Memphis.
Arch Otolaryngol Head Neck Surg. 1994 Nov;120(11):1261-6. doi: 10.1001/archotol.1994.01880350067012.
We tested the in vitro and in vivo growth effects of estradiol and tamoxifen citrate to determine whether patients with laryngeal carcinoma could benefit from antiestrogen therapy as demonstrated for cancers of other estrogen-responsive organs.
A comparison of growth effects of the hormones relative to controls by using a tetrazolium dye reduction assay and nude mice.
Two estrogen-positive laryngeal carcinoma cell lines (UMSCC5 and UMSCC11B) and athymic mice were used.
There were marked growth inhibitory effects of tamoxifen alone in concentrations of 3 to 8 mumol/L on both cell lines. There were no in vitro growth effects of estradiol-17 beta alone in concentrations of 0.1 to 9.6 mumol/L, but there was antagonism of the estradiol to the growth inhibitory effects of tamoxifen. In athymic mice, estradiol markedly stimulated the growth of UMSCC5, whereas tamoxifen inhibited growth.
These results support the concept of chemotherapeutic growth inhibition of estrogen receptor-positive laryngeal cancer with antiestrogens.
我们测试了雌二醇和枸橼酸他莫昔芬的体外和体内生长效应，以确定喉癌患者是否能像其他雌激素反应性器官的癌症那样从抗雌激素治疗中获益。
通过使用四氮唑蓝还原试验和裸鼠，比较激素与对照的生长效应。
使用两种雌激素阳性喉癌细胞系（UMSCC5和UMSCC11B）和无胸腺小鼠。
单独使用浓度为3至8μmol/L的他莫昔芬对两种细胞系均有明显的生长抑制作用。浓度为0.1至9.6μmol/L的单独17β-雌二醇无体外生长效应，但雌二醇对他莫昔芬的生长抑制效应有拮抗作用。在无胸腺小鼠中，雌二醇显著刺激UMSCC5的生长，而他莫昔芬抑制生长。
这些结果支持用抗雌激素对雌激素受体阳性喉癌进行化疗性生长抑制的概念。
